ASH 2025: Rigel's CEO Raul Rodriguez discusses the company's IRAK1/4 data in patients with lower-risk MDS
He describes how Rigel became focused on both on both IRAK 1 and 4, a novel mechanism in the area of hematology, and what is next for the company after the ASH presentation.
--------
10:13
--------
10:13
ASH 2025: CEO Will West describes how CellCentric is seeing results for its oral p300/CBP inhibitor, Inobrodib, in heavily refractory multiple myeloma patients
Shares an update on the company's ASH data, and also on plans to move into earlier lines of treatment. A registrational study is already set to begin in early 2026.
--------
7:12
--------
7:12
ASH 2025: Disc Medicine CEO John Quisel walks us through the RALLY-MF Phase 2 trial data of DISC-0974 in anemia of myelofibrosis
He says that this interim update, which is studying 50mg every 4 weeks for up to 6 treatments, is showing response rates in line with an earlier dose escalation study that was presented at ASH last year. Plus, a quick regulatory update on bitopertin.
--------
17:45
--------
17:45
ASH 2025: Orca Bio has an April 6th PDUFA date from FDA for its cell therapy product, Orca-T, that aims to solve the problem of treatment-related toxicities that come with stem cell transplants
Co-Founder and CEO Nate Fernhoff walks us through this platform and the clinical data that Orca has previously announced, and new data at ASH. Plus, a journey through the patient experience of how this works.
--------
12:14
--------
12:14
ASH 2025: Kite Pharma EVP Cindy Perettie discusses today's new data for the pivotal IMMagine-1 study of the BCMA CAR-T, anito-cell. Plus, the future of dual antigen and in vivo CAR-Ts.
She highlights anito-cell's new efficacy data, and a safety profile that continues to look clean. Plus, she thinks a CD19 + CD20 dual antigen CAR-T could be best in class in the future, and why Kite acquired an in vivo CAR-T company in August for $350M.
España